Arch Therapeutics Correlations
| ARTH Stock | USD 0.21 0.01 5.00% |
The correlation of Arch Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Arch Therapeutics Correlation With Market
Significant diversification
The correlation between Arch Therapeutics and DJI is 0.03 (i.e., Significant diversification) for selected investment horizon. Overlapping area represents the amount of risk that can be diversified away by holding Arch Therapeutics and DJI in the same portfolio, assuming nothing else is changed.
Arch |
The ability to find closely correlated positions to Arch Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Arch Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Arch Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Arch Therapeutics to buy it.
Moving together with Arch OTC Stock
| 0.67 | BKRKF | PT Bank Rakyat | PairCorr |
| 0.73 | BKRKY | Bank Rakyat | PairCorr |
| 0.71 | TLK | Telkom Indonesia Tbk | PairCorr |
| 0.7 | PPERF | Bank Mandiri Persero | PairCorr |
| 0.7 | PPERY | Bank Mandiri Persero | PairCorr |
| 0.78 | MRK | Merck Company Fiscal Year End 6th of February 2025 | PairCorr |
Moving against Arch OTC Stock
| 0.86 | CSCO | Cisco Systems Sell-off Trend | PairCorr |
| 0.84 | AA | Alcoa Corp Fiscal Year End 15th of January 2025 | PairCorr |
| 0.8 | PTAIF | PT Astra International | PairCorr |
| 0.8 | HPQ | HP Inc | PairCorr |
| 0.8 | CVX | Chevron Corp Sell-off Trend | PairCorr |
| 0.79 | AXP | American Express Fiscal Year End 24th of January 2025 | PairCorr |
| 0.75 | CAT | Caterpillar Fiscal Year End 3rd of February 2025 | PairCorr |
| 0.74 | SSNLF | Samsung Electronics | PairCorr |
| 0.73 | HD | Home Depot | PairCorr |
| 0.7 | WMT | Walmart Aggressive Push | PairCorr |
| 0.68 | XOM | Exxon Mobil Corp Fiscal Year End 7th of February 2025 | PairCorr |
| 0.63 | T | ATT Inc Fiscal Year End 22nd of January 2025 | PairCorr |
| 0.41 | TLKMF | Telkom Indonesia Tbk | PairCorr |
| 0.38 | IBM | International Business Fiscal Year End 22nd of January 2025 | PairCorr |
| 0.35 | GE | GE Aerospace Fiscal Year End 28th of January 2025 | PairCorr |
Related Correlations Analysis
| Click cells to compare fundamentals | Check Volatility | Backtest Portfolio |
Correlation Matchups
Over a given time period, the two securities move together when the Correlation Coefficient is positive. Conversely, the two assets move in opposite directions when the Correlation Coefficient is negative. Determining your positions' relationship to each other is valuable for analyzing and projecting your portfolio's future expected return and risk.High positive correlations
| High negative correlations
|
Risk-Adjusted Indicators
There is a big difference between Arch OTC Stock performing well and Arch Therapeutics OTC Stock doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Arch Therapeutics' multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.| Mean Deviation | Jensen Alpha | Sortino Ratio | Treynor Ratio | Semi Deviation | Expected Shortfall | Potential Upside | Value @Risk | Maximum Drawdown | ||
|---|---|---|---|---|---|---|---|---|---|---|
| BIOAF | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||
| ATBPF | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||
| AWKNF | 9.62 | 1.55 | 0.06 | (0.24) | 11.26 | 19.14 | 93.51 | |||
| CMVLF | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||
| AKESF | 4.13 | 1.01 | 0.14 | (57.69) | 3.86 | 12.00 | 41.83 | |||
| ADYX | 7.45 | 2.32 | 0.00 | 1.75 | 0.00 | 0.00 | 266.67 | |||
| AVXT | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||
| BCDAW | 17.63 | 1.89 | 0.06 | (1.10) | 18.27 | 57.25 | 139.50 | |||
| ADILW | 25.83 | 4.83 | 0.11 | (0.53) | 25.95 | 95.66 | 199.49 |
Be your own money manager
Our tools can tell you how much better you can do entering a position in Arch Therapeutics without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Economic Indicators Now
Economic IndicatorsTop statistical indicators that provide insights into how an economy is performing |
| All Next | Launch Module |
Arch Therapeutics Corporate Management
Elected by the shareholders, the Arch Therapeutics' board of directors comprises two types of representatives: Arch Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Arch. The board's role is to monitor Arch Therapeutics' management team and ensure that shareholders' interests are well served. Arch Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Arch Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Michael Abrams | Chief Officer | Profile | |
| Daniel Yrigoyen | VP Sales | Profile | |
| Terrence MD | Chairman, CoFounder | Profile | |
| Daniel Wadsworth | Advisor Commercialization | Profile | |
| Steven Kates | VP Technology | Profile | |
| Rutledge EllisBehnke | CoFounder Advisor | Profile |